Deutschland - Deutsch - BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte)

teva gmbh (3086597) - fluconazol - hartkapsel - teil 1 - hartkapsel; fluconazol (23145) 100 milligramm

Deutschland - Deutsch - BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte)

teva gmbh (3086597) - fluconazol - hartkapsel - teil 1 - hartkapsel; fluconazol (23145) 50 milligramm

Deutschland - Deutsch - BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte)

städtisches klinikum karlsruhe ggmbh (8051818) - thrombozyten vom menschen - suspension - thrombozyten vom menschen (21445) teilchen pro transfusionseinheit

Deutschland - Deutsch - BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte)

städtisches klinikum karlsruhe ggmbh (8051818) - thrombozyten vom menschen, bestrahlt mit 30 gy ((bestrahlung erfolgt zur zerstörung der proliferationsfähigkeit kernhaltiger zellen)) - suspension - teil 1 - suspension; thrombozyten vom menschen, bestrahlt mit 30 gy ((bestrahlung erfolgt zur zerstörung der proliferationsfähigkeit kernhaltiger zellen)) (28906) teilchen pro transfusionseinheit

Deutschland - Deutsch - BVL (Bundesamt für Verbraucherschutz und Lebensmittelsicherheit)

cheminova deutschland gmbh - emulsion, Öl in wasser - 100 g/l zeta-cypermethrin - insektizid

Europäische Union - Deutsch - EMA (European Medicines Agency)

novartis europharm limited - tisagenlecleucel - precursor b-cell lymphoblastic leukemia-lymphoma; lymphoma, large b-cell, diffuse - andere antineoplastische mittel - kymriah is indicated for the treatment of:• paediatric and young adult patients up to and including 25 years of age with b cell acute lymphoblastic leukaemia (all) that is refractory, in relapse post transplant or in second or later relapse. • adult patients with relapsed or refractory diffuse large b cell lymphoma (dlbcl) after two or more lines of systemic therapy. • adult patients with relapsed or refractory follicular lymphoma (fl) after two or more lines of systemic therapy.

Europäische Union - Deutsch - EMA (European Medicines Agency)

kite pharma eu b.v. - axicabtagene ciloleucel - lymphoma, follicular; lymphoma, large b-cell, diffuse - antineoplastische mittel - yescarta is indicated for the treatment of adult patients with diffuse large b cell lymphoma (dlbcl) and high-grade b-cell lymphoma (hgbl) that relapses within 12 months from completion of, or is refractory to, first-line chemoimmunotherapy. yescarta is indicated for the treatment of adult patients with relapsed or refractory (r/r) dlbcl and primary mediastinal large b cell lymphoma (pmbcl), after two or more lines of systemic therapy. yescarta is indicated for the treatment of adult patients with r/r follicular lymphoma (fl) after three or more lines of systemic therapy.

Europäische Union - Deutsch - EMA (European Medicines Agency)

bristol-myers squibb pharma eeig - idecabtagene vicleucel - multiple myeloma; neoplasms; cancer; neoplasms, plasma cell; hemostatic disorders; vascular diseases; cardiovascular diseases; paraproteinemias; blood protein disorders; hematologic diseases; hemic and lymphatic diseases; hemorrhagic disorders; infectious mononucleosis; lymphoproliferative disorders; immunoproliferative disorders; immune system diseases - antineoplastische mittel - abecma is indicated for the treatment of adult patients with relapsed and refractory multiple myeloma who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor and an anti cd38 antibody and have demonstrated disease progression on the last therapy.

Europäische Union - Deutsch - EMA (European Medicines Agency)

celltrion healthcare hungary kft. - regdanvimab - covid-19 virus infection - immunseren und immunglobuline, - regdanvimab is indicated for the treatment of adults with coronavirus disease 2019 (covid-19) who do not require supplemental oxygen and who are at increased risk of progressing to severe covid-19.

Europäische Union - Deutsch - EMA (European Medicines Agency)

astrazeneca ab - tixagevimab, cilgavimab - covid-19 virus infection - prevention of covid-19.